Navidea Biopharma Balance Sheet - Quarterly (NYSEMKT:NAVB)

Add to My Stocks
$0.21 $0.01 (5%) NAVB stock closing price Jul 13, 2018 (Closing)

The financial analysis of a company like Navidea Biopharma involves checking the three financial statements of the company in detail, of which the balance sheet is one. As in our Navidea Biopharma stock analysis, analyzing a company also involves looking at the company's assets and liabilities as given in its balance sheet, which can be used to measure financial performance. Quarterly results are typically accompanied with the company releasing financial statements. The balance sheet shows total liabilities of $13.37M and shareholders equity of $4.94M. Navidea Biopharma revenue and Navidea Biopharma operating cash flow are important in understanding the financial capacity of the company.

View and download Navidea Biopharma quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Marketable Securities1.39M1.79M1.99M1.99M------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets1.05M1.1M--1.07M1.01M---1.05M
Total Current Assets
Property Plant & Equipment1.2M1.2M1.71M1.68M3.21M3.58M3.58M3.79M3.86M3.87M
Accumulated Depreciation--1.39M1.35M2.11M2.33M2.21M2.16M2.07M1.94M
Net Property Plant & Equipment
Investment & Advances-4.8M6.44M8.06M9.43M-----
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets1.43M1.44M--------
Total Assets
Notes Payable2.35M51.95M-4.38M4.09M2.75M----
Accounts Payable--1.23M1.6M3.13M7.12M4.89M5.13M2.9M1.76M
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses8.94M4.74M2.49M4.01M1.17M8.46M7.2M4.92M3.06M3.03M
Income Taxes Payable----------
Other Current Liabilities----3.56M2.31M---1.04M
Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt-----9.64M10.54M9.51M10.67M60.74M
Non-Current Capital Leases----------
Other Long-Term Liabilities--------1.65M1.67M
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus331.46M331.12M331.03M330.97M330.8M326.56M326.57M326.38M326.44M326.08M
Retained Earnings-327.34M-319.9M-315.85M-314.46M-309.27M-394.85M-390.97M-390.91M-384.23M-380.54M
Treasury Stock----------
Other Liabilities----------
Shareholders Equity4.94M12.04M16.01M17.34M22.36M-67.66M-63.77M-63.9M-57.16M-53.83M
Total Liabilities & Shareholders Equity18.32M20.78M22.6M25.9M32.92M12.46M11.18M8.68M12.28M14.96M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Most investors just check the Navidea Biopharma stock price, and Navidea Biopharma historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Navidea Biopharma PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: An asset is a resource that a corporation like Navidea Biopharma owns and has monetary significance. NAVB assets decreased from $20.78M in 2017 Q4 to $18.32M in 2018 Q1. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities: This item on the balance sheet implies the firm's, in this case Navidea Biopharma's, legal obligations including loans, accounts payable, deferred revenue, accrued expenses and mortgages. The total liabilities for NAVB stock stand at $13.37M.

Navidea Biopharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio